News
Academy
Editorial PodcastsEditorial VideosProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Pharmaceutical Executive APEX Awards
  • Latest Executive Roundtables
  • Asembia 2025
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

UK: NICE Responds to ABPI Legal Challenge to Budget Impact Test

September 28, 2017
By Leela Barham
Article

Leela Barham looks at the reasons behind the Association of the British Pharmaceutical Industry's bid to legally challenge NICE's proposed introduction of the budget impact test.

The Association of the British Pharmaceutical Industry (ABPI) has sought permission for a Judicial Review (JR) for the introduction of a new budget impact test. Under the changes from the National Institute for Health and Care Excellence (NICE) – with NHS England (NHSE), the agency paying for many specialized, expensive medicines – access could be ‘phased and delayed’ whilst negotiations are conducted between NHSE and the company. That would be the case even if NICE found the drug to be cost-effective, but where it has a high budget impact. High in this case is defined as costing more than £20 million ($26m) in any of the first three years after launch.

The budget impact test is in addition to a number of other ways that pricing and reimbursement are shaped; not least is the Pharmaceutical Price Regulation Scheme (PPRS). Under the 2014 PPRS, members of the voluntary scheme have already paid back over a billion.

The ABPI applied for permission to legally challenge the introduction of the budget impact test (and other changes tabled too with respect to ultra-orphan drugs) on the July 10, 2017. Few details were available then about the details of the legal challenge with the ABPI issuing just a short press release and not commenting further.

More details are emerging now. The Times published a piece on 25 September which reveals a little of how NICE is responding. According to The Times – who have seen court papers – NICE has raised the issue of the independence of Adrian Towse, a proposed witness from the ABPI.

Adrian Towse is the head of the Office of Health Economics (OHE), an organization that aims to “supper better health care policies by providing insightful economic and statistical analyses of critical issues” according to their website. The Times suggests that the OHE is little known, but it is a big name in industry and policy circles. It’s also owned by the ABPI, and receives a lot of money from industry through research grants and consulting. On that basis, NICE says that Towse is plainly not independent and questions if his evidence can be properly admissible. The OHE itself would see itself as independent, with independent committees supporting its work.

NICE is also questioning the legal action on the basis that the ABPI filed its claim at the last moment. At the permission stage of a JR, Paul Ranson, Consultant – Contractor at Morgan, Lewis & Bockius UK LLP, explains that the court may refuse permission for a JR where there has been an unjustified delay in bringing the claim. Technically the changes were to be introduced from April, but in practice it’s likely they could only apply for a drug not-yet-appraised, so it’s unclear when the real start date would have been (although NICE and NHSE presumably knew with a forward work-plan of drugs to be appraised).

Time will tell if the ABPI will be granted permission, but expect NICE – and NHSE – to fight back.

 

Recent Videos
Arda Ural
Lynlee Brown
Arda Ural
Related Content

Impact, Access, and Scale: The Potential of India’s Pharma Market

Impact, Access, and Scale: The Potential of India’s Pharma Market

Roshel Jayasundera;Joshua Siow;Bhavna Desai
May 8th 2025
Article

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.


Justin Holko

A Global Approach to Oncology: Q&A with Justin Holko

Mike Hollan
April 28th 2025
Article

The Regeneron SVP details the company’s approach to reaching oncology patients across the planet.


Bill Coyle

Predicting and Planning for Tariff Impacts: Q&A with Bill Coyle

Mike Hollan
April 25th 2025
Article

The chaotic tariff situation is forcing pharma companies to prepare for multiple outcomes.


Marcel Botha

The Risks and Opportunities of Tariffs: Q&A with Marcel Botha

Mike Hollan
April 25th 2025
Article

While supply chain interruptions are a strong possibility, the tariffs also provide the industry with a chance to improve certain conditions.


Bringing Biotech Innovation Across Borders

Bringing Biotech Innovation Across Borders

Ed Ahn
April 17th 2025
Article

Four tips for midsized companies when entering new global markets.


Stock.adobe.com

ABPI Restores Novo Nordisk’s Membership

Mike Hollan
March 21st 2025
Article

The pharmaceutical company had previously been subjected to a 2-year suspension.

Related Content

Impact, Access, and Scale: The Potential of India’s Pharma Market

Impact, Access, and Scale: The Potential of India’s Pharma Market

Roshel Jayasundera;Joshua Siow;Bhavna Desai
May 8th 2025
Article

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.


Justin Holko

A Global Approach to Oncology: Q&A with Justin Holko

Mike Hollan
April 28th 2025
Article

The Regeneron SVP details the company’s approach to reaching oncology patients across the planet.


Bill Coyle

Predicting and Planning for Tariff Impacts: Q&A with Bill Coyle

Mike Hollan
April 25th 2025
Article

The chaotic tariff situation is forcing pharma companies to prepare for multiple outcomes.


Marcel Botha

The Risks and Opportunities of Tariffs: Q&A with Marcel Botha

Mike Hollan
April 25th 2025
Article

While supply chain interruptions are a strong possibility, the tariffs also provide the industry with a chance to improve certain conditions.


Bringing Biotech Innovation Across Borders

Bringing Biotech Innovation Across Borders

Ed Ahn
April 17th 2025
Article

Four tips for midsized companies when entering new global markets.


Stock.adobe.com

ABPI Restores Novo Nordisk’s Membership

Mike Hollan
March 21st 2025
Article

The pharmaceutical company had previously been subjected to a 2-year suspension.

About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.